Vaxcyte (PCVX) Cash from Investing Activities (2019 - 2026)

Vaxcyte (PCVX) has reported Cash from Investing Activities for 8 consecutive years, with -$233.4 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Cash from Investing Activities fell 289.28% year-over-year to -$233.4 million; the TTM figure through Mar 2026 stood at $80.6 million (up 105.63% YoY), while the FY2025 annual figure was $437.4 million, up 121.81% from the prior year.
• Cash from Investing Activities eased to -$233.4 million in Q1 2026 per PCVX's latest filing, from $115.1 million in the prior quarter.
• Across five years, Cash from Investing Activities topped out at $123.3 million in Q1 2025 and bottomed at -$917.0 million in Q3 2024.
• Historically, Cash from Investing Activities has averaged -$147.1 million across 5 years, with a median of -$13.9 million in 2023.
• On a YoY basis, Cash from Investing Activities climbed as much as 287.91% in 2022 and fell as far as 43943.9% in 2022.
• Vaxcyte's Cash from Investing Activities stood at -$36.0 million in 2022, then soared by 61.27% to -$13.9 million in 2023, then sank by 3900.92% to -$557.2 million in 2024, then soared by 120.66% to $115.1 million in 2025, then plunged by 302.74% to -$233.4 million in 2026.
• Business Quant data shows PCVX's Cash from Investing Activities at -$233.4 million in Q1 2026, $115.1 million in Q4 2025, and $121.2 million in Q3 2025.